Meta description: A not yet recruiting trial in Paris evaluates a deep learning based classifier for colonic neoplasms on CT scans to support treatment decisions.
Publication date context: 2026-02-13. Clinicians, researchers, and regulatory teams should monitor this study as it progresses through regulatory review.
What changed in colon tumor classification on CT with deep learning?
The project centers on a classifier designed to examine CT images and assign a category to colon tumors to inform treatment options. The trial description notes colonic neoplasm as the condition and lists two sponsors: Assistance Publique Hôpitaux de Paris and Institut National de Recherche en Informatique et Automatique. The status is not yet recruiting, indicating the approach is in early development and awaiting regulatory alignment.
As imaging based analytical methods mature, this effort exemplifies how artificial intelligence powered tools may contribute to multidisciplinary decision making. Because the information comes from a ClinicalTrials.gov record, readers should refer to the linked page for the most current status and sponsor details.
How is the study designed and who is involved?
The entry describes a Paris based collaboration intended to evaluate a deep learning based classifier that supports radiology informed decisions for colon neoplasms. The sponsors listed are the Assistance Publique Hôpitaux de Paris and the Institut National de Recherche en Informatique et Automatique. The record shows the study as not yet recruiting and provides a direct ClinicalTrials.gov link in the source. No enrollment results are reported at this stage.
Design wise, the work appears to focus on development and regulatory alignment rather than immediate clinical deployment. Stakeholders should anticipate further documentation on data governance, safety validation, software verification, and performance targets as the project advances toward potential regulatory submission.
What is the regulatory context for this approach?
In general terms, a deep learning based classifier used to classify colon tumors on CT as decision support for treatment would be considered a medical device or software as a medical device under many regulatory frameworks. The current record does not publish an intended use beyond classification and treatment decision support, nor does it provide performance data. Regulatory planning will require a defined intended use, risk assessment, data handling practices, and a plan for clinical evaluation. The sponsor statements in the record are the source of truth for the device status and regulatory pathway at this time.
Professionals should monitor updates to the sponsor communication, trial status changes, and any labeling material that accompanies future submissions. The MDR style approach emphasizes clear labeling and robust validation in order to ensure patient safety and accurate clinical interpretation of imaging results.
What are the safety and efficacy considerations at this stage?
With no results yet reported, the safety and efficacy profile remains unknown. Any future deployment would require formal risk management, software validation, clinical evidence, and post market surveillance where applicable. The MDR framework generally requires a comprehensive technical documentation package, software verification and validation, and a clinical evaluation plan to support claims of safety and performance. Stakeholders should await formal disclosures from the sponsor before drawing conclusions about effect on patient care.
FAQ
- 1. What is the focus of this trial? The focus is an advanced algorithm to classify colon tumors on CT to inform treatment decisions.
- 2. Who sponsors the work? Assistance Publique Hôpitaux de Paris and Institut National de Recherche en Informatique et Automatique.
- 3. What is the trial status? Not yet recruiting.
- 4. Where is the study conducted? At Paris based institutions.
- 5. How can readers learn more? See the trial page on ClinicalTrials.gov.
Conclusion
In summary this early stage work signals progress toward integrating deep learning based imaging analysis into colon cancer treatment planning. Regulators will review the intended use, data governance, validation strategy, and performance targets as the project moves forward. For readers it is important to track the official sponsor updates and the ClinicalTrials.gov entries for the most current information.
Disclaimer
This article is intended for healthcare professionals and regulators. It is not legal advice. For regulatory guidance contact a qualified regulatory affairs professional.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07406958?term=medical+device